Live Breaking News & Updates on Kathleenn Moore

Stay updated with breaking news from Kathleenn moore. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Moore Details Ongoing Research Aiming to Fill Unmet Needs in Ovarian Cancer

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress ....

United States , University Of Oklahoma , Oklahoma City , Dana Farber Cancer Institute , Joycef Liu , Kathleenn Moore , Floortjej Backes , Shannonn Westin , University Of Oklahoma Health Stephenson Cancer Center , University Of Texas Md Anderson Cancer Center , Ohio State University Comprehensive Cancer Center , European Medicines Agency , Phasei Program , Stephenson Cancer Center , Clinical Research , University Of Oklahoma College Medicine , Science Summit , Gynecologic Oncology , Oklahoma College , Christina Washington , Oklahoma Health Stephenson Cancer Center , James Cancer Hospital , Cancer Center , Ovarian Cancer ,

Mirvetuximab soravtansine-gynx beneficial for FRα-positive ovarian cancer, finds phase 3 trial

Mirvetuximab soravtansine-gynx beneficial for FRα-positive ovarian cancer, finds phase 3 trial
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Kathleenn Moore , Mirvetuximab Soravtansine , University Of Oklahoma Health Sciences Center , Stephenson Cancer Center Section Of Gynecologic Oncology , New England Journal , Stephenson Cancer Center Section , Gynecologic Oncology , Oklahoma Health Sciences Center , Oklahoma City , Platinum Resistant Ovarian Cancer ,

Immune-Targeted Therapy Continues to Fall Short in Ovarian Cancer

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer. ....

United States , University Of Oklahoma , Oklahoma City , Kathleenn Moore , Clinical Research , University Of Oklahoma College Medicine , Phasei Program , Stephenson Cancer Center , Science Summit , Gynecologic Oncology , Oklahoma College ,

Dr Moore on Continued Efforts to Utilize Immunotherapy in Ovarian Cancer

Kathleen N. Moore, MD, MS, discusses continued efforts to target the immune system in ovarian cancer through the use of immunotherapy, as well as alternative strategies being explored in this tumor type. ....

University Of Oklahoma , United States , Kathleenn Moore , University Of Oklahoma College Medicine , Phasei Program , Stephenson Cancer Center , Clinical Research , Gynecologic Oncology , Oklahoma College , Ovarian Cancer , Onclive Tv ,

Raludotatug Deruxtecan Elicits Early Efficacy and Safety in Platinum-Resistant Ovarian Cancer

The emerging CDH6-directed antibody-drug conjugate raludotatug deruxtecan had a manageable safety profile, generated pharmacokinetic activity, and produced early evidence of clinical response in patients with heavily pretreated, platinum-resistant ovarian cancer. ....

Kathleenn Moore , Daiichi Sankyo , Speaker For Research To Practice , Clinical Research , Oklahoma City , Research To Practice , Great Debates , Raludotatug Deruxtecan , R Dxd , Ovarian Cancer , Cdh6 Directed Antibody Drug Conjugate ,